Neoplastic Brain, Glioblastoma, and Immunotherapy
IGF-I, insulin-like growth factor 1, is present in normal fetal/neonatal brain development and reappears in the mature brain participating in the development of malignant tumor, glioblastoma multiforme. Targeting the IGF-I system has emerged as a useful method to reduce glial malignant development....
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2020
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/67421 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1879164696887558144 |
|---|---|
| author | Trojan, Annabelle Kasprzak, Heliodor Gutierrez, Oscar Penagos, Pedro Briceno, Ignacio Siachoque, Heber O. Anthony, Donald D. Alvarez, Alvaro Trojan, Jerzy |
| author_browse | Alvarez, Alvaro Anthony, Donald D. Briceno, Ignacio Gutierrez, Oscar Kasprzak, Heliodor Penagos, Pedro Siachoque, Heber O. Trojan, Annabelle Trojan, Jerzy |
| author_facet | Trojan, Annabelle Kasprzak, Heliodor Gutierrez, Oscar Penagos, Pedro Briceno, Ignacio Siachoque, Heber O. Anthony, Donald D. Alvarez, Alvaro Trojan, Jerzy |
| author_sort | Trojan, Annabelle |
| building | IntechOpen |
| collection | Acceso abierto |
| description | IGF-I, insulin-like growth factor 1, is present in normal fetal/neonatal brain development and reappears in the mature brain participating in the development of malignant tumor, glioblastoma multiforme. Targeting the IGF-I system has emerged as a useful method to reduce glial malignant development. Downregulation in the expression of IGF-I using antigene anti-IGF-I technology (antisense, AS, and triple helix, TH) applied in glioma cell culture established from glioblastoma biopsies induces the expression of B7 and MHC-I antigens in transfected cells (immunogenicity). The transfected cancer cells, “vaccines,” after subcutaneous injection, initiated an immune response mediated by T CD8+ lymphocytes, followed by tumor regression (immunotherapy). The median survival of patients treated by surgery followed by radiotherapy and immunotherapy was 21–24 months. On the other side, the experimental work has demonstrated that IGF-I AS or TH transfected tumor cells fused with activated dendritic cells, DC, showing more striking immunogenic character. Using IGF-I TH/DC “vaccination,” the efficiency in suppressing rat glioma tumors is not only relatively higher than that obtained using IGF-I TH cells but is also more rapid. |
| doi_str_mv | 10.5772/intechopen.84726 |
| first_indexed | 2026-10-15T21:38:27Z |
| format | Book Chapter |
| fullrecord | <oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><identifier>intech-67421</identifier><datestamp>2020-01-29</datestamp>
<dc:title>Neoplastic Brain, Glioblastoma, and Immunotherapy</dc:title>
<dc:creator>Annabelle Trojan</dc:creator>
<dc:creator>Heliodor Kasprzak</dc:creator>
<dc:creator>Oscar Gutierrez</dc:creator>
<dc:creator>Pedro Penagos</dc:creator>
<dc:creator>Ignacio Briceno</dc:creator>
<dc:creator>Heber O. Siachoque</dc:creator>
<dc:creator>Donald D. Anthony</dc:creator>
<dc:creator>Alvaro Alvarez</dc:creator>
<dc:creator>Jerzy Trojan</dc:creator>
<dc:subject>Health Sciences</dc:subject>
<dc:description>IGF-I, insulin-like growth factor 1, is present in normal fetal/neonatal brain development and reappears in the mature brain participating in the development of malignant tumor, glioblastoma multiforme. Targeting the IGF-I system has emerged as a useful method to reduce glial malignant development. Downregulation in the expression of IGF-I using antigene anti-IGF-I technology (antisense, AS, and triple helix, TH) applied in glioma cell culture established from glioblastoma biopsies induces the expression of B7 and MHC-I antigens in transfected cells (immunogenicity). The transfected cancer cells, “vaccines,” after subcutaneous injection, initiated an immune response mediated by T CD8+ lymphocytes, followed by tumor regression (immunotherapy). The median survival of patients treated by surgery followed by radiotherapy and immunotherapy was 21–24 months. On the other side, the experimental work has demonstrated that IGF-I AS or TH transfected tumor cells fused with activated dendritic cells, DC, showing more striking immunogenic character. Using IGF-I TH/DC “vaccination,” the efficiency in suppressing rat glioma tumors is not only relatively higher than that obtained using IGF-I TH cells but is also more rapid.</dc:description>
<dc:publisher>IntechOpen</dc:publisher>
<dc:date>2020-01-29</dc:date>
<dc:type>Chapter, Part Of Book</dc:type>
<dc:identifier>https://www.intechopen.com/chapters/67421</dc:identifier>
<dc:identifier>doi:10.5772/intechopen.84726</dc:identifier>
<dc:language>en</dc:language>
<dc:relation>ISBN:978-1-78984-157-2</dc:relation>
<dc:rights>https://creativecommons.org/licenses/by/3.0/</dc:rights>
<dc:source>https://www.intechopen.com/books/7864 ; Brain and Spinal Tumors - Primary and Secondary</dc:source>
</oai_dc:dc> |
| id | intech-67421 |
| institution | IntechOpen |
| isbn | 978-1-78984-157-2 |
| language | English |
| last_indexed | 2026-10-15T21:38:27Z |
| publishDate | 2020 |
| publishDateRange | 2020 |
| publishDateSort | 2020 |
| publisher | IntechOpen |
| publisherStr | IntechOpen |
| record_format | oai_dc |
| spelling | intech-674212020-01-29 Neoplastic Brain, Glioblastoma, and Immunotherapy Annabelle Trojan Heliodor Kasprzak Oscar Gutierrez Pedro Penagos Ignacio Briceno Heber O. Siachoque Donald D. Anthony Alvaro Alvarez Jerzy Trojan Health Sciences IGF-I, insulin-like growth factor 1, is present in normal fetal/neonatal brain development and reappears in the mature brain participating in the development of malignant tumor, glioblastoma multiforme. Targeting the IGF-I system has emerged as a useful method to reduce glial malignant development. Downregulation in the expression of IGF-I using antigene anti-IGF-I technology (antisense, AS, and triple helix, TH) applied in glioma cell culture established from glioblastoma biopsies induces the expression of B7 and MHC-I antigens in transfected cells (immunogenicity). The transfected cancer cells, “vaccines,” after subcutaneous injection, initiated an immune response mediated by T CD8+ lymphocytes, followed by tumor regression (immunotherapy). The median survival of patients treated by surgery followed by radiotherapy and immunotherapy was 21–24 months. On the other side, the experimental work has demonstrated that IGF-I AS or TH transfected tumor cells fused with activated dendritic cells, DC, showing more striking immunogenic character. Using IGF-I TH/DC “vaccination,” the efficiency in suppressing rat glioma tumors is not only relatively higher than that obtained using IGF-I TH cells but is also more rapid. IntechOpen 2020-01-29 Chapter, Part Of Book https://www.intechopen.com/chapters/67421 doi:10.5772/intechopen.84726 en ISBN:978-1-78984-157-2 https://creativecommons.org/licenses/by/3.0/ https://www.intechopen.com/books/7864 ; Brain and Spinal Tumors - Primary and Secondary |
| spellingShingle | Health Sciences Trojan, Annabelle Kasprzak, Heliodor Gutierrez, Oscar Penagos, Pedro Briceno, Ignacio Siachoque, Heber O. Anthony, Donald D. Alvarez, Alvaro Trojan, Jerzy Neoplastic Brain, Glioblastoma, and Immunotherapy |
| title | Neoplastic Brain, Glioblastoma, and Immunotherapy |
| title_full | Neoplastic Brain, Glioblastoma, and Immunotherapy |
| title_fullStr | Neoplastic Brain, Glioblastoma, and Immunotherapy |
| title_full_unstemmed | Neoplastic Brain, Glioblastoma, and Immunotherapy |
| title_short | Neoplastic Brain, Glioblastoma, and Immunotherapy |
| title_sort | neoplastic brain glioblastoma and immunotherapy |
| topic | Health Sciences |
| url | https://www.intechopen.com/chapters/67421 |
| work_keys_str_mv | AT trojanannabelle neoplasticbrainglioblastomaandimmunotherapy AT kasprzakheliodor neoplasticbrainglioblastomaandimmunotherapy AT gutierrezoscar neoplasticbrainglioblastomaandimmunotherapy AT penagospedro neoplasticbrainglioblastomaandimmunotherapy AT bricenoignacio neoplasticbrainglioblastomaandimmunotherapy AT siachoquehebero neoplasticbrainglioblastomaandimmunotherapy AT anthonydonaldd neoplasticbrainglioblastomaandimmunotherapy AT alvarezalvaro neoplasticbrainglioblastomaandimmunotherapy AT trojanjerzy neoplasticbrainglioblastomaandimmunotherapy |